News
D. Boral Capital LLC acted as exclusive placement agent for the Transaction.
The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback